Hou D Y, Hamburger A W, Beach J L, Maruyama Y
Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore 21201.
Cancer Invest. 1989;7(6):543-50. doi: 10.3109/07357908909017528.
The ability of a [111In]bleomycin complex [( 111In]BLMC) to kill five cell lines of human lung cancer (small cell lung cancer) was investigated. Cells were exposed to either 0.9% NaCl, [111In]Cl3, BLM, [111In]BLMC, nonradioactive InCl3, or In-BLMC for 60 minutes, plated in soft agarose, and assessed for colony formation. [111In]BLMC (40-200 microCi carried by 15-25 micrograms BLM/ml) was more cytotoxic than BLM (15-25 micrograms BLM/ml) by a factor of 1.6-5.3 for five cell lines. The percent survival of N417 cells was 28.4 for [111In]BLMC (40 microCi/15 micrograms BLM/ml) and 54.3 for BLM (15 micrograms/ml); 1.9 for [111In]BLMC (200 microCi/25 micrograms BLM/ml), and 10.0 for BLM (25 micrograms/ml). 111InCl3 (200 microCi/ml) and nonradioactive InCl3 failed to inhibit colony formation. The new [111In]BLMC may be useful for therapy of some lung cancer patients.
研究了[111铟]博来霉素复合物（[111In]BLMC）对五种人肺癌细胞系（小细胞肺癌）的杀伤能力。将细胞分别暴露于0.9%氯化钠、[111In]氯化铟、博来霉素、[111In]BLMC、非放射性氯化铟或铟-博来霉素中60分钟，接种于软琼脂糖中，并评估集落形成情况。对于五种细胞系，[111In]BLMC（每毫升含15 - 25微克博来霉素，携带40 - 200微居里）的细胞毒性比博来霉素（每毫升15 - 25微克博来霉素）高1.6 - 5.3倍。对于N417细胞，[111In]BLMC（40微居里/15微克博来霉素/毫升）的存活率为28.4%，博来霉素（15微克/毫升）为54.3%；[111In]BLMC（200微居里/25微克博来霉素/毫升）为1.9%，博来霉素（25微克/毫升）为10.0%。[111In]氯化铟（200微居里/毫升）和非放射性氯化铟未能抑制集落形成。新型[111In]BLMC可能对某些肺癌患者的治疗有用。
